공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

편두통 : 파이프라인 리뷰

Migraine (Central Nervous System) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 232767
페이지 정보 영문 363 Pages
가격
US $ 2,000 ₩ 2,367,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,735,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,102,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


편두통 : 파이프라인 리뷰 Migraine (Central Nervous System) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 363 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

편두통은 심한 두통이 반복되는 것이 특징이며, 보통 머리의 어느 한 쪽만 욱신욱신 아프게 됩니다. 이러한 두통은 구역질, 구토, 빛과 소리에 대한 과민반응을 동반합니다. 증상에는 함묵, 얼굴과 팔, 어깨가 따끔따끔한 통증, 한쪽 눈 뒤쪽의 통증, 일상적인 신체 움직임 악화 등이 있습니다.

편두통(Migraine) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

편두통 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Migraine, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021 (Contd..2)
  • Number of Products under Development by Companies, 2021 (Contd..3)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Companies, 2021 (Contd..3)
  • Products under Development by Companies, 2021 (Contd..4)
  • Products under Development by Companies, 2021 (Contd..5)
  • Products under Development by Companies, 2021 (Contd..6)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • Number of Products by Stage and Target, 2021 (Contd..2)
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..2)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Migraine - Pipeline by 4P Therapeutics LLC, 2021
  • Migraine - Pipeline by AbbVie Inc, 2021
  • Migraine - Pipeline by Acadia Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Achelios Therapeutics Inc, 2021
  • Migraine - Pipeline by Acorda Therapeutics Inc, 2021
  • Migraine - Pipeline by AEON Biopharma Inc, 2021
  • Migraine - Pipeline by AgoneX Biopharmaceuticals Inc, 2021
  • Migraine - Pipeline by Allodynic Therapeutics LLC, 2021
  • Migraine - Pipeline by Amgen Inc, 2021
  • Migraine - Pipeline by AOBiome LLC, 2021
  • Migraine - Pipeline by Aptarion Biotech AG, 2021
  • Migraine - Pipeline by Asarina Pharma AB, 2021
  • Migraine - Pipeline by Assertio Therapeutics Inc, 2021
  • Migraine - Pipeline by AstraZeneca Plc, 2021
  • Migraine - Pipeline by Astrocyte Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Avanir Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Axsome Therapeutics Inc, 2021
  • Migraine - Pipeline by Benuvia Therapeutics Inc, 2021
  • Migraine - Pipeline by Better Life Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Biogen Inc, 2021
  • Migraine - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
  • Migraine - Pipeline by Blackthorn Therapeutics Inc, 2021
  • Migraine - Pipeline by Cerecin Pte Ltd, 2021
  • Migraine - Pipeline by Charleston Laboratories Inc, 2021
  • Migraine - Pipeline by Citragen Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Corium Inc, 2021
  • Migraine - Pipeline by Crossject SA, 2021
  • Migraine - Pipeline by Curatis AG, 2021
  • Migraine - Pipeline by DelNova Inc, 2021
  • Migraine - Pipeline by Eli Lilly and Co, 2021
  • Migraine - Pipeline by Epalex Corp, 2021
  • Migraine - Pipeline by Exxel Pharma Inc, 2021
  • Migraine - Pipeline by H. Lundbeck AS, 2021
  • Migraine - Pipeline by IACTA Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by InKemia IUCT Group SA, 2021
  • Migraine - Pipeline by IntelGenx Corp, 2021
  • Migraine - Pipeline by Invisio Ltd, 2021
  • Migraine - Pipeline by Ionis Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Kissei Pharmaceutical Co Ltd, 2021
  • Migraine - Pipeline by Klaria Pharma Holding AB, 2021
  • Migraine - Pipeline by Lateral Pharma Pty Ltd, 2021
  • Migraine - Pipeline by MannKind Corp, 2021
  • Migraine - Pipeline by Medytox Inc, 2021
  • Migraine - Pipeline by Merck & Co Inc, 2021
  • Migraine - Pipeline by Microgen, 2021
  • Migraine - Pipeline by NAL Pharmaceuticals Ltd, 2021
  • Migraine - Pipeline by NeurAxon Pharma Inc, 2021
  • Migraine - Pipeline by NeuroPharm Inc, 2021
  • Migraine - Pipeline by NutriBand Inc, 2021
  • Migraine - Pipeline by OWP Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Panaxia Pharmaceutical Industries Ltd, 2021
  • Migraine - Pipeline by Pharmnovo AB, 2021
  • Migraine - Pipeline by Pherin Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Promius Pharma LLC, 2021
  • Migraine - Pipeline by Pulmatrix Inc, 2021
  • Migraine - Pipeline by Qingdao Chia Tai Haier Pharmaceutical Co Ltd, 2021
  • Migraine - Pipeline by RAFT Pharmaceuticals, 2021
  • Migraine - Pipeline by Revance Therapeutics Inc, 2021
  • Migraine - Pipeline by Satsuma Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Seurat Therapeutics Inc, 2021
  • Migraine - Pipeline by Shandong Boan Biotechnology Co Ltd, 2021
  • Migraine - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
  • Migraine - Pipeline by Shin Nippon Biomedical Laboratories Ltd, 2021
  • Migraine - Pipeline by Sorrento Therapeutics Inc, 2021
  • Migraine - Pipeline by Suda Pharmaceuticals Ltd, 2021
  • Migraine - Pipeline by Teva Pharmaceutical Industries Ltd, 2021
  • Migraine - Pipeline by Trevena Inc, 2021
  • Migraine - Pipeline by Trigemina Inc, 2021
  • Migraine - Pipeline by TrioxBio Inc, 2021
  • Migraine - Pipeline by Vaxxinity Inc, 2021
  • Migraine - Pipeline by Xenon Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Xoc Pharmaceuticals Inc, 2021
  • Migraine - Pipeline by Zosano Pharma Corp, 2021
  • Migraine - Dormant Projects, 2021
  • Migraine - Dormant Projects, 2021 (Contd..1)
  • Migraine - Dormant Projects, 2021 (Contd..2)
  • Migraine - Dormant Projects, 2021 (Contd..3)
  • Migraine - Dormant Projects, 2021 (Contd..4)
  • Migraine - Dormant Projects, 2021 (Contd..5)
  • Migraine - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Migraine, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Drugs In Development, 2021, provides an overview of the Migraine (Central Nervous System) pipeline landscape.Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 9, 21, 10, 1, 34, 5 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Migraine - Overview
  • Migraine - Therapeutics Development
  • Migraine - Therapeutics Assessment
  • Migraine - Companies Involved in Therapeutics Development
  • Migraine - Drug Profiles
  • Migraine - Dormant Projects
  • Migraine - Discontinued Products
  • Migraine - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q